Literature DB >> 11004369

Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels.

C N Lee1, W F Cheng, C A Chen, J S Chu, C Y Hsieh, F J Hsieh.   

Abstract

OBJECTIVE: To evaluate the relationship between blood flow in the tumor assessed by color Doppler ultrasound, microvessel density, and vascular endothelial growth factor levels in endometrial carcinoma.
METHODS: Forty-nine patients undergoing surgery for endometrial carcinoma were enrolled. Transvaginal color Doppler ultrasound was performed preoperatively and the lowest resistance index (RI) in the tumor was recorded for analysis. Vascular endothelial growth factor in the tumor was quantified by enzyme immunoassay. The microvessel density of the excised tumor was assessed immunohistochemically. The relationships between the corresponding RI, microvessel density, and vascular endothelial growth factor level of the tumor tissues and clinical and pathologic parameters were analyzed.
RESULTS: Significantly lower RIs were noted in tumors of stage II or greater (0.37 compared with 0.50, P <.001), of high histologic grade (grade 3) (0.34 compared with 0.49, P =.004), with deep myometrial invasion (one-half depth or greater) (0.39 compared with 0.49, P =.002), with lymphovascular emboli (0.38 compared with 0.49, P <.001), or with lymph node metastasis (0.30 compared with 0.49, P <.001) compared with stage I tumors and tumors of histologic grade 1 or 2, with superficial myometrial invasion, without lymphovascular emboli, or with no lymph node metastasis. Increased vascular endothelial growth factor levels and microvessel density (x200 field) also were detected in tumors of stage II or greater (975 compared with 129 pg/mg, P =.014; and 88 compared with 61, P =.018, respectively), with lymphovascular emboli (1138 compared with 120 pg/mg, P =.002; and 86 compared with 63, P =.023), or with lymph node metastasis (1011 compared with 95 pg/mg, P <.001; and 98 compared with 61, P =. 019). Resistance index, microvessel density, and vascular endothelial growth factor levels in the tumor showed linear correlations (RI compared with microvessel density: r = -.32, P =. 03; RI compared with vascular endothelial growth factor levels: r = -.40, P =.004; microvessel density compared with vascular endothelial growth factor levels: r =.36, P =.011).
CONCLUSION: Blood flow assessed by color Doppler ultrasound has histologic and biologic correlations with angiogenesis and vascular endothelial growth factor levels and might play an important role in predicting tumor progression and metastasis in endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11004369     DOI: 10.1016/s0029-7844(00)00976-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

Review 2.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

3.  Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Authors:  Sami K Saarelainen; Synnöve Staff; Nina Peltonen; Terho Lehtimäki; Jorma Isola; Paula M Kujala; Maarit H Vuento; Johanna U Mäenpää
Journal:  Tumour Biol       Date:  2014-01-14

4.  A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Authors:  Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2014-03-01       Impact factor: 5.482

Review 5.  Recent Advances in Endometrial Cancer.

Authors:  Arthur-Quan Tran; Paola Gehrig
Journal:  F1000Res       Date:  2017-01-27

6.  Effects of compound Kushen injection on pathology and angiogenesis of tumor tissues.

Authors:  Hongyan Wang; Haiyan Hu; Hua Rong; Xuwei Zhao
Journal:  Oncol Lett       Date:  2018-12-21       Impact factor: 2.967

Review 7.  New therapies for advanced, recurrent, and metastatic endometrial cancers.

Authors:  Vicky Makker; Angela K Green; Robert M Wenham; David Mutch; Brittany Davidson; David Scott Miller
Journal:  Gynecol Oncol Res Pract       Date:  2017-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.